SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on Marshall Edwards and its novel oncology programs at the JMP Securities Healthcare Conference on Monday, September 27, 2010 beginning at 4:30 p.m. EDT from the New York Palace Hotel. A live webcast of the presentation can be accessed at www.marshalledwardsinc.com. A replay will be available approximately one hour after the presentation and archived for 30 days.
About Marshall Edwards
Marshall Edwards, Inc. (NASDAQ: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from an investigational isoflavone technology platform that has generated a number of compounds with anti-proliferative tumor activity. These small molecules are believed to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. The Company's lead programs focus on two groups of compounds with related but distinct mechanisms of action. The first and most advanced is its NADH oxidase program, a family of compounds that includes Triphendiol and NV-143. The second is its novel mTORC1 and mTORC2 pathway inhibitor program, which includes NV-128 and NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.
|SOURCE Marshall Edwards, Inc.|
Copyright©2010 PR Newswire.
All rights reserved